LWM
HRTX icon

Lodestone Wealth Management’s Heron Therapeutics HRTX Stock Holding History

Lodestone Wealth Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-250
Closed -$325 – 798
2025
Q4 		$325 Buy
+250
New +$309 ﹤0.01% 773

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $2.3B AUM 29.92% 1-Year Est. Return

Lodestone Wealth Management's HRTX Position: Q1 2026 in Review

Lodestone Wealth Management sold out of Heron Therapeutics (HRTX) in Q1 2026, closing a stake of 250 shares — an estimated $325 sold.

Lodestone Wealth Management first reported a position in HRTX in Q4 2025 and held it in 1 quarter. The position peaked at $325 in Q4 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Lodestone Wealth Management reported no remaining Heron Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Lodestone Wealth Management sold 250 Heron Therapeutics shares in Q1 2026, an estimated $325.
  • Lodestone Wealth Management first reported a position in Heron Therapeutics in Q4 2025 and held it in 1 quarter.
  • Lodestone Wealth Management's Heron Therapeutics position peaked at $325 in Q4 2025.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Lodestone Wealth Management's 13F filing for Q1 2026, filed 1 May 2026.